The treatment combined SCINTIX biology-guided radiotherapy with “conventional” stereotactic body radiotherapy to simultaneously target the patient’s lung tumor and a solid tumor located in another area of the body, according to a Sept. 5 news release shared with Becker’s. The hospital is part of Yale New Haven Health.
SCINTIX radiotherapy uses positron emission tomography data and reacts to a lung or bone tumor’s motion during treatment, allowing radiation to be delivered more precisely. At the same time, stereotactic body radiotherapy can target a solid tumor in a different location.
The multi-target treatment is delivered in five fractions or fewer, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.